Identity
Roche Farma, S.A.
| Year | Amount | Distribution |
|---|---|---|
| 2026* | €226.9M | |
| 2025 | €168.1M | |
| 2024 | €114.7M | |
| + regional platforms | ||
| 2023 | €70.2M | |
| 2022 | €89.2M | |
| 2021 | €46.5M | |
| 2020 | €14.7M | |
| 2019 | €63.2M | |
| 2018 | €0.6M | |
| 2017 | €2.1M | |
| 2016 | €<0.1M | |
In figures
Volume
Between 2016 and 2026 it won 982 contracts worth €796M on its own, with 53 buyers. Its 11 joint-venture (UTE) contracts are shown separately.
Price
It has fewer than 3 comparable awards, too few to compute its median discount.
Competition
Since 2024, 0% of its comparable value was won with a discount and against other bidders. It was the only bidder in 94% of its contracts (2016–2026).
Renewals
86 contracts (€50.2M) come up for tender again in the next 24 months.
A UTE is a temporary joint venture: the contract is awarded to the UTE and each partner's share is not published. That is why these contracts are not added to Roche Farma, S.A.'s total, and under «Show UTEs» the amounts are the full value of each contract (100%), not Roche Farma, S.A.'s share.
Data up to 31 October 2026 · updated on 12 November 2026 · Source: official data, national and regional coverage
| UTE partners | Contracts | Total value (100 %) |
|---|
Its discounts
The discount at which it wins contested contracts, year by year.
Only 2 contested awards can be compared — not enough to read how it prices. Of its 982 contracts, 620 are call-offs under framework agreements and 162 were awarded without competition (negotiated without publicity or direct award).
Framework call-offs 620 · Single bidder 46 · Non-competitive procedure 162 · No comparable budget 152 · Contested, comparable 2
Where it wins, and at what discount
In the report · these discounts, one by one
Each dot on the chart is an award. The report lists them all and groups them by buyer and by sector, next to the discounts of other companies with the same buyers.
Full list: date, buyer, amount, budget, discount, bidders and a link to the official publication.
How it wins
Whether it wins with or without competition.
84% of the comparable value since 2024 (€25.3M of €30.0M) was won at the tender price and without other bidders. €4.72M (16%) was awarded with a discount and without other bidders.
Comparable: 37 awards with a published budget and bidder count (€30.0M of €510M awarded since 2024). Percentages of value; the figure next to «bidders» is the number of awards. Source: official data, national and regional coverage.
Between 2016 and 2026, 69.0% of the value was awarded through negotiated without publicity procedure (48.6% of contracts); followed by Based on a framework agreement (9.7%) and Open (9.0%).
Upcoming tenders and main buyers
When its contracts come back and who it sells to.
In the next 24 months 86 of its contracts come up for tender again, worth €50.2M.
and 81 more in the next 24 months · the report includes them all
Expected end year from the published duration (no extensions). The report includes the month and the discount it won each one at.
| Buyer | Contracts | Value, € | Period |
|---|---|---|---|
| OSAKIDETZA - Servicio Vasco de Salud -Director General | 31 | 155 M | 2024–2026 |
| Gerencia de Servicio Sanitarios de Fuerteventura | 571 | 135 M | 2018–2026 |
| Subsecretaría de la Consellería de Sanidad y Salud Pública | 22 | 110 M | 2020–2026 |
| Servicio Andaluz de Salud | 43 | 82 M | 2024–2026 |
| Dirección General de Planificación Económica | 33 | 46 M | 2018–2026 |
and 48 more buyers
Between 2016 and 2026, 100.0% of the value it won on its own is in Medical & pharmaceuticals (CPV 33, 966 contracts).
Recent awards
The evidence behind every insight in the report.
| Date | Contract | Buyer | Bidders | Value |
|---|---|---|---|---|
| 03/07/2026 | Suministro de medicamentos de uso humano tipo II (Exclusivos), con destino al Servicio de Farmacia … | Dirección Gerente del Hospital Universitario Nuestra Señora de Candelaria | 1 | €85.7k |
| 08/06/2026 | cpca 1º cbam roche farma, s.a. exp. 578/2025 suministro medicamento exclusivos cca: +6.i+e0q8j, am … | Servicio Andaluz de Salud | 1 | €1.87M |
| 03/06/2026 | Suministro de medicamentos de uso humano tipo ii (exclusivos), lote 160, con destino al servicio de… | Dirección Gerente del Hospital Universitario Nuestra Señora de Candelaria | 1 | €5.61k |
| 17/04/2026 | Suministro de 10.000 envases de Baloxavir (Xofluza) para la Reserva Estratégica Nacional | Dirección del Instituto Nacional de Gestión Sanitaria (INGESA) | 1 | €433k |
| 14/04/2026 | 1º cbam exp. 771/2025 am con varias empresas por el que se fijan las condiciones para el suministro… | Servicio Andaluz de Salud | 1 | €159k |